Drug Type Nanobody |
Synonyms- |
Target |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Invetx, Inc.Startup |
Active Organization Invetx, Inc.Startup |
Inactive Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cardiovascular Diseases | Discovery | - | Invetx, Inc.Startup | 04 Jul 2024 |
Digestive System Disorders | Discovery | - | Invetx, Inc.Startup | 04 Jul 2024 |
Endocrinology and Metabolic Disease | Discovery | - | Invetx, Inc.Startup | 04 Jul 2024 |
Hematologic Diseases | Discovery | - | Invetx, Inc.Startup | 04 Jul 2024 |
Immune System Diseases | Discovery | - | Invetx, Inc.Startup | 04 Jul 2024 |
Neoplasms | Discovery | - | Invetx, Inc.Startup | 04 Jul 2024 |
Nervous System Diseases | Discovery | - | Invetx, Inc.Startup | 04 Jul 2024 |
Skin and Musculoskeletal Diseases | Discovery | - | Invetx, Inc.Startup | 04 Jul 2024 |
Urogenital Diseases | Discovery | - | Invetx, Inc.Startup | 04 Jul 2024 |